Predictors of Thyroid Tumor Aggressiveness

Western Journal of Medicine

Volumn 165, Issue 3, 1996, Pages 131-138

  Clark, Orlo H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CANCER INVASION; CANCER STAGING; FEMALE; HUMAN; LYMPHADENECTOMY; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL; THYROID TUMOR; TREATMENT OUTCOME;

ADULT; FEMALE; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 0030237961     PISSN: 00930415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Nishiyama RH, Ludwig GK, Thompson NW: The prevalence of small papillary thyroid carcinomas in 100 consecutive necropsies in an American population, In DeGroot LJ, Frohman LA, Kaplan EL (Eds): Radiation-Associated Thyroid Carcinoma. New York, NY, Grune & Stratton, 1977, pp 123-134
2. Robbins J, Merino MJ, Boice JD Jr, et al: Thyroid cancer: A lethal endocrine neoplasm. Ann Intern Med 1991; 115:133-145
3. Mazzaferri EL: Papillary and fotlicular thyroid cancer: A selective approach to diagnosis and treatment. Annu Rev Med 1981; 32:73-91
4. Mazzaferri EL: Papillary thyroid carcinoma: Factors influencing prognosis and current therapy. Semin Oncol 1987; 14:315-332
5. Mazzaferri EL, Young RL: Papillary thyroid carcinoma: A 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70:511-518
6. DeGroot LJ, Kaplan EL, McCormick M, Straus FH: Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol 1990; 7:414-424
7. Clark OH, Gerend PL: Thyrotropin-receptor adenylate cyclase system in Hurthle cell neoplasms. J Clin Endocrinol Metab 1985; 61:773-778
8. Emerick ET, Dun GY, Siperstein AE, Burrow GN, Clark OH: Diagnosis, treatment, and outcome of follicular thyroid cancer. Cancer 1993; 72:3287-3295
9. Shah JP, Medina JE, Shaha AR, Schantz SP, Marti JR: Cervical lymph node metastasis. Curr Probl Surg 1993; 30:1-335
10. Samaan NA, OrdoJE, Shaha AR, Schantz SP, Marti JR: Cervical lymph node metastasis. Curr Probl Surg 1993;
11. Demeter JG, De Jong SA, Lawrence AM, Paloyan E: Anaplastic thyroid carcinoma: Risk factors and outcome. Surgery 1991; 110:956-961
12. Sakamoto A, Kasai N, Sugano H: Poorly differentiated carcinoma of the thyroid: A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 1983; 52:1849-1855
13. Hay ID: Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990; 19:545-576
14. Hay ID, Grant CS, Taylor WF, McConahey WM: Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: A retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987; 102:1088-1095
15. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF: Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1986; 61:978-996
16. Hedinger C, Williams ED, Sobin LH: Histological Typing of Thyroid Tumours, Vol 11, 2nd edition - World Health Organization International Histological Classification of Tumours. New York, NY, Springer-Verlag, 1988
17. Schelfhout LJDM, Creutzberg CL, Hamming JF, et al: Multivariate analysis of survival in differentiated thyroid cancer: The prognostic significance of the age factor. Eur J Cancer Clin Oncol 1988; 24:331-337
18. Schröder S, Dralle H, Rehpenning W, Böcker W: [Prognostic criteria in papillary thyroid carcinoma.] Langenbecks Arch Chir 1987; 371:263-280 [Engl Abstr]
19. Byar DP, Green SB, Dor P, et al: A prognostic index for thyroid carcinoma: A study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer 1979; 15:1033-1041
20. Hay ID: Prognostic factors in thyroid carcinoma. Thyroid Today 1989; 12:1
21. Cady B, Rossi R: An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104:947-953
22. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS: Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1,779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114:1050-1057
23. Harness JK, Thompson NW, Nishiyama RH: Childhood thyroid carcinoma. Arch Surg 1971; 102:278-284
24. La Quaglia MP, Corbally MT, Heller O, Exelby PR, Brerman MF: Recurrence and morbidity in differentiated thyroid carcinoma in children. Surgery 1988; 104:1149-1156
25. 131I in the treatment of thyroid cancers. Thyroid Today 1993; 16:1-9
26. Pasieka JL, Thompson NW, McLeod MK, Burney RE, Macha M: The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg 1992; 16:711-716
27. Harwood J, Clark OH, Dunphy JE: Significance of lymph node metastases in differentiated thyroid cancer. Am J Surg 1978; 136:107-112
28. Tennvall J, Biörklund A, Möller T, Ranstam J, Akerman M: Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? - Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow-up. Cancer 1986; 57:1405-1414
29. Tubiana M, Schlumberger M, Rougier P, et al: Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985; 55:794-804
30. Asselain FB, Savoie JC, O'Hubert E, et al: Multifactorial study of prognostic factors indifferentiated thyroid carcinoma and re-evaluation of the importance of age. Br J Surg 1986; 73:274-277
31. Bäckdahl M, Carstensen J, Auer G, Tallroth E: Statistical evaluation of the prognostic value of nuclear DNA content in papillary, follicular, and medullary thyroid tumours. World J Surg 1986; 10:974-980
32. Bäckdahl M, Wallin A, Auer G, et al: Cellular DNA content in thyroid tumors: A reliable factor for grading and prognosis. Prog Surg 1988; 19:40-53
33. Joensuu H, Klemi P, Eerola E, Tuominen J: Influence of cellular DNA content on survival in differentiated thyroid carcinoma. Cancer 1986; 58:2462-2467
34. Hay ID, Bergstralh EJ, Grant CS, et al: Nuclear DNA Content in Papillary Thyroid Carcinoma: Relationship to Patient Age and Other Conventional Prognostic Factors. Proceedings of the 63rd Annual Meeting of the American Thyroid Association, Montreal, Quebec, 1988, abstract T52
35. Schlumberger M, Tubiana M, De Vathaire F, et al: Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63:960-967
36. Maxon HR III, Smith HS: Radioiodine 131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19:685-718
37. Siperstein A, Zeng QH, Gum ET, Levin KE, Clark OH: Adenylate cyclase activity as a predictor of thyroid tumor aggressiveness. World J Surg 1988; 12:528-533
38. Duh Q Y, Gum ET, Gerend PL, Raper SE, Clark OH: Epidermal growth factor receptors in normal and neoplastic thyroid tissue. Surgery 1985; 98:1000-1007
39. Goretzki PE, Lyons J, Stacy-Phipps S, et al: Mutational activation of ras and gsp oncogenes in differentiated thyroid cancer and their biological implications. World J Surg 1992; 16:576-582
40. Ito T, Seyama T, Mizuno T, et al: Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992; 52:1369-1371
41. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP: High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993; 91:179-184
42. Zou M, Shi Y, Farid NR: p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab 1993; 77:1054-1058
43. Smith SA, Hay ID, Goellner JR, Ryan JJ, McConahey WM: Mortality from papillary thyroid carcinoma - A case-control study of 56 lethal cases. Cancer 1988; 62:1381-1388
44. Suarez HG, du Villard JA, Caillou B, Schlumberger M, Parmentier C, Monier R: Gsp mutations in human thyroid tumours. Oncogene 1991; 6:677-679
45. Lyons J, Landis CA, Harsh G, et al: Two G protein oncogenes in human endocrine tumors. Science 1990; 249:655-658
46. O'Sullivan C, Barton CM, Staddon SL, Brown CL, Lemoine NR: Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol Carcinog 1991; 4:345-349
47. Lemoine NR, Mayall ES, Wyllie FS, et al: High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989; 4:159-164
48. Wright PA, Williams ED, Lemoine NR, Wynford-Thomas D: Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation. Oncogene 1991; 6:471-473
49. Witt TR, Meng RL, Economou SG, Southwick HW: The approach to the irradiated thyroid. Surg Clin North Am 1979; 59:45-63
50. Johnson TL, Lloyd RV, Thor A: Expression of ras oncogene p21 antigen in normal and proliferative thyroid tissues. Am J Pathol 1987; 127:60-65
51. Pacini F, Basolo F, Fugazzola U, et al: Expression of the ras Gene Product (p21) in Primary and Metastatic Differentated Thyroid Cancer: Possible Predictor of Poor Outcome. Presented at the 19th European Thyroid Association Meeting, Hannover, Germany, 1991
52. Fusco A, Grieco M, Santoro M, et al: A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987; 328:170-172
53. Donghi R, Sozzi G, Pierotti MA, et al: The oncogene associated with human papillary thyroid carcinoma (PTC) is assigned to chromosome 10q11-q12 in the same region as multiple endocrine neoplasia type 2A (MEN2A). Oncogene 1989; 4:521-523
54. Wright PA, Lemoine NR, Goretzki PE, et al: Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene 1991; 6:1693-1697
55. Noguchi S, Noguchi A, Murakami N: Papillary carcinoma of the thyroid - I. Development pattern of metastasis. Cancer 1970; 26:1053-1060
56. Noguchi S, Noguchi A, Murakami N: Papillary carcinoma of the thyroid - II. Value of prophylactic lymph node excision. Cancer 1970; 26:1061-1064
57. Cady B, Sedgwick CE, Meissner WA, Brokwatter JR, Romagosa V, Werber J: Changing clinical pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma. Ann Surg 1976; 184:541-553
58. Spires JR, Robbins KT, Luna MA, Byers RM: Metastatic papillary carcinoma of the thyroid: The significance of extranodal extension. Head Neck 1989; 11:242-246
59. Hutter RV, Frazell EL, Foote FW Jr: Elective radical neck dissection: An assessment of its use in the management of papillary thyroid cancer. Cancer 1970; 20:87-93
60. Russell MA, Gilbert EF, Jaeschke WF: Prognostic features of thyroid cancer - A long-term follow-up of 68 cases. Cancer 1975; 36:553-559
61. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H: Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994; 18:559-567
62. Harness JK, Thompson NW, McCleod MK, Pasieka JL: Differentiated thyroid carcinoma in children and adolescents. World J Surg 1992; 16:547-555
63. Clark OH: Endocrine Surgery of the Thyroid and Parathyroid Glands. St Louis, Mo, CV Mosby, 1985
64. 131I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab 1973; 36:1143-1152
65. Massin JP, Savoie JC, Gamier H, Guiraudon G, Leger FA, Bacourt F: Pulmonary metastases in differentiated thyroid carcinoma - Study of 58 cases with implications for the primary tumor treatment. Cancer 1984; 53:982-992
66. Casara D, Rubella D, Saladini G, et al: Differenl features of pulmonary metastases in differentiated thyroid cancer: Natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993; 34:1626-1631
67. Wong JB, Kaplan MM, Meyer KB, Parker SG: Ablative radioactive iodine therapy for apparently localized thyroid carcinoma - A decision analytic perspective. Endocrinol MetabClin North Am 1990; 19:741-760
68. Cady B, Cohn K, Rossi RL, et al: The effect of Ihyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. Surgery 1983; 94:978-983
69. Crile G Jr: A second opinion about thyroid hormone treatment (Letter). Surgery 1988; 103:268-269
70. Pacini F, Cetani F, Miccoli P, et al: Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 1994; 18:600-604
71. Wilson SM, Block GE: Carcinoma of the thyroid metastatic to lymph nodes of the neck. Arch Surg 1971; 102:285-291
72. 131I scans: Utility in well differentiated thyroid cancer (Abstr). J Nucl Med 1992; 33:894
73. Solomon BL, Wartofsky L, Burman KD: Current trends in the management of well-differentiated papillary thyroid carcinoma. J Clin Endocrinol Metabol 1996; 81:333-339
74. Clark OH, Hoelting T: Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans. Thyroid 1994; 4:501-505
75. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J: Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metabol 1995; 80:1488-1492
76. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C: Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988; 29:1790-1794
77. Pacini F, Pinchera A, Giani C, Grasso L, Baschieri L: Serum thyroglobulin concentrations and 1311 whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). Clin Endocrinol (Oxf) 1980; 13:107-110